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Summary
Therapeutic angiogenesis with vascular endothelial
growth factor (VEGF) is a clinically promising strategy
in ischaemic disease. The pathophysiological consequences
of enhanced vessel formation, however, are poorly
understood. We established mice overexpressing human
VEGF165 under a neuron-specific promoter, which exhib-
ited an increased density of brain vessels under physiolo-
gical conditions and enhanced angiogenesis after brain
ischaemia. Following transient intraluminal middle cere-
bral artery (MCA) occlusions, VEGF overexpression
significantly alleviated neurological deficits and infarct
volume, and reduced disseminated neuronal injury and
caspase-3 activity, confirming earlier observations that
VEGF has neuroprotective properties. Brain swelling
was not influenced in VEGF-overexpressing animals,
while sodium fluorescein extravasation was moderately
increased, suggesting that VEGF induces a mild blood–
brain barrier leakage. To elucidate whether enhanced
angiogenesis improves regional cerebral blood flow in
the ischaemic brain, [14C]iodoantipyrine autoradiography
was performed. Autoradiographies revealed that VEGF
induces haemodynamic steal phenomena with reduced
blood flow in ischaemic areas and increased flow values
only outside the MCA territory. Our data demonstrate
that VEGF protects neurons from ischaemic cell death
by a direct action rather than by promoting angiogenesis,
and suggest that strategies aiming at increasing vascular
density in the whole brain, e.g. by VEGF overexpression,
may worsen rather than improve cerebral haemo-
dynamics after stroke.
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Introduction
Vascular endothelial growth factor-A (VEGF-A or VEGF) is
a homodimeric angiogenic growth factor existing in at least
five isoforms (VEGF121, VEGF145, VEGF165, VEGF189 and
VEGF206), which differ in their capability to bind heparin-
rich matrix components and receptors (Robinson and Stringer,
2001). VEGF is ubiquitously expressed in the brain mainly by
choroid plexus epithelial cells, but also by astrocytes and
neurons (Monacci et al., 1993; Marti and Risau, 1998). In
brain hypoxia and ischaemia, VEGF expression is induced
through transcriptional activation via hypoxia-inducible fac-
tor (HIF)-1 and HIF-2 (Forsythe et al., 1996; Ema et al., 1997;
Marti and Risau, 1998; Marti et al., 2000).
Therapeutic angiogenesis with VEGF appears to be pro-
mising in limb ischaemia, coronary heart disease and ischae-
mic stroke (Folkman, 1998; Isner and Asahara, 1999; Marti
and Risau, 1999). Initial clinical trials have been encouraging
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(Baumgartner et al., 1998; Hendel et al., 2000) and led to
the ‘vascular endothelial growth factor in ischemia for vas-
cular angiogenesis’ (VIVA) trial, a double blind, placebo-
controlled study investigating the efficacy of VEGF in
patients with chronic myocardial ischaemia (Henry et al.,
2003). Although there was no evidence for an amelioration
of myocardial perfusion within 60 days treatment, patients
receiving high-dose VEGF had a significant improvement in
their angina class by day 120 (Henry et al., 2003).
A number of reasons encourage VEGF treatment after
stroke. First, VEGF is naturally expressed in the brain and
upregulated by hypoxia (Marti and Risau, 1998; Marti et al.,
2000) and, thus, is part of an endogenous adaptive system to
protect the brain from ischaemia (Marti et al., 2000). Secondly,
VEGF delivery increases capillary density in the ischaemic
brain (Zhang et al., 2000; Sun et al., 2003) and thereby
might improve cerebral blood flow (CBF) in haemodynamically
compromised brain areas. Thirdly, numerous in vitro studies
have demonstrated that VEGF is a potent neurotrophic factor
which also confers protection to injured neurons (Silverman
et al., 1999; Sondell et al., 1999; Jin et al., 2000; Marti, 2002).
As a consequence, local intracerebroventricular delivery of
VEGF recently has been shown to decrease brain injury
after transient focal ischaemia (Sun et al., 2003).
Potentially detrimental effects, on the other hand, might
compromise beneficial actions of VEGF. For example, VEGF
has been involved in the development of vascular leakage
after brain hypoxia as causative factor (Schoch et al., 2002).
In fact, early post-ischaemic systemic delivery of VEGF
increased blood–brain barrier (BBB) leakage and tissue
damage after stroke, while VEGF antagonization with the
high-affinity VEGF-binding protein mFlt(1–3)-IgG improved
neurological outcome as well as reduced brain oedema and
infarct size (van Bruggen et al., 1999; Zhang et al., 2000).
At present, it is unknown whether VEGF-induced angiogen-
esis indeed improves cerebral haemodynamics after stroke.
The latter assumption, however, is critical for the concept
of therapeutic angiogenesis. To elucidate the consequences
of increased vessel formation, we have established transgenic
mice overexpressing VEGF in the brain, using a cDNA encod-
ing the human VEGF165 isoform under control of two neuron-
specific promoters. These mice developed an increased global
density of morphologically and functionally normal capil-
laries, without concomitant vascular leakage under physiolo-
gical conditions (Vogel et al., 2004). We now submitted these
mice to focal cerebral ischaemia, using intraluminal middle
cerebral artery (MCA) occlusions of two different durations
(90 or 30 min), and examined the effects of brain-selective
VEGF overexpression on injury development, BBB dysfunc-
tion, angiogenesis and cerebral haemodynamics.
Materials and methods
Construction of plasmids
The neuron-specific enolase (NSE)-VEGF165 plasmid was con-
structed by insertion of a 1794 bpEcl136II–HindIII rat NSE promoter
fragment (Forss-Petter et al., 1990) into the HincII- and HindIII-
digested plasmid pVRBpA, containing a 587 bp human VEGF165
cDNA and the 281 bp bovine growth hormone poly(A) signal
sequence. The plasmid pVRBpA was constructed by excision of the
human VEGF165 cDNA from the plasmid CMV-hVEGF by EcoRI
and EcoRV digestion and insertion into the plasmid pPGKneobpA
which contained, after digestion with XbaI, filling in overhanging
ends and digestion with EcoRI, the bovine growth hormone poly(A)
signal sequence. Subsequently, a 2700 bp fragment, containing the
rat NSE promoter, the human VEGF165 cDNA and the poly(A)
signal sequence (Fig. 1A), was cleaved from the plasmid backbone
by digestion with Acc65I and NotI, and the gel-isolated fragment
was purified by Qiaex (Qiagen, Hilden, Germany). The N-methyl-
D-aspartate receptor (NMDAR)-VEGF165 plasmid was constructed
by inserting a 870 bp fragment containing the human VEGF165
cDNA and the bovine growth hormone poly(A) signal sequence,
which was prepared by digesting the plasmid pVRBpA with EcoRI,
filling in overhanging ends and digestion with NotI, into the plasmid
pMK40. The plasmid pMK40, which contains a 5.5 kb genomic
fragment of the e2 subunit of the mouse NMDAR spanning from
the promoter to intron 3 (Klein et al., 1998), was digested with KasI
and, after filling in overhanging ends, further digested with NotI,
leaving a 2300 bp fragment spanning from the promoter to the end
of exon 3. Subsequently, a 3100 bp fragment, containing the NMDAR
e2 genomic fragment, the human VEGF165 cDNA and the poly(A)
signal sequence (Fig. 1A), was cleaved from the plasmid backbone
by digestion with XhoI, and purified as described above.
Generation and characterization of
VEGF-overexpressing mice
The purified linearized DNA was microinjected into the pronuclei of
fertilized mouse oocytes, isolated from superovulated (C57BL/6 3
C3H/He)F1 hybrid mice. Microinjected oocytes were then implanted
into pseudopregnant females of the same hybrid mouse strain. After
screening DNA samples of the litters, we bred transgenic founders
with C57BL/6 wild-type mice (Harlan, Borchen, Germany) to estab-
lish the transgenic lines TgN(NSEVEGF)1651–1653 (V1–V3) and
TgN(NMDARVEGF)1654–1658 (V4–V8). Detection of the human
VEGF transgene was performed by in situ hybridization and enzyme-
linked immunosorbent assay (ELISA).
Polymerase chain reaction (PCR)-based
screening for VEGF transgene
Genomic DNA was prepared from mouse tail biopsies, and geno-
typing was performed by PCR analysis on a Perkin Elmer Thermal
Cycler using Taq polymerase (Promega) and the primer pair
HVBPA405 (50-AGGAGAGATGAGCTTCCTACAG-30) and RV1B
(50-GATGGCTGGCAACTAGAAGGCAC-30). Reaction conditions
were as follows: 94C for 1 min for initial denaturation; 30 cycles of:
94C for 1 min, 65C for 1 min, 72C for 2 min, followed by a final
elongation at 72C for 6 min. The product of 277 bp was visualized
on the agarose gel with ethidium bromide.
In situ hybridization
In situ hybridizations were performed using [35S]UTP-labelled RNA
probes for mouse VEGF (cross-reacting with human VEGF) as
described (Breier et al., 1992; Marti and Risau, 1998).
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Preparation of brain extracts and measurement
of VEGF protein
Tissue lysates from brain hemispheres were prepared as detailed
before (Marti et al., 2000). Mouse and human VEGF was quantified
using commercially available immunoassay kits specific for mouse
(Quantikine M, R&D Systems) and human (Quantikine, R&D
Systems) VEGF.
Induction of MCA occlusions
Animal experiments were carried out with governmental approval
according to NIH guidelines for care and use of laboratory animals.
Adult VEGF-overexpressing mice (transgenic; derived from the V1
line) and their non-transgenic littermates (21–28 g) were anaesthe-
tized with 1% halothane (30% O2, remainder N2O) [n = 11/group
(90 min ischaemia) and n = 7–8/group (30 min MCA occlusion)].
Rectal temperature was maintained between 36.5 and 37.0C using a
feedback-controlled heating system. Focal ischaemia was induced
using an intraluminal technique as previously described (Hata et al.,
2000; Hermann et al., 2001a), using a 8-0 silicon-coated (Xantopren:
Bayer Dental, Osaka, Japan) nylon monofilament (Ethilon; Ethicon,
Norderstedt, Germany). During the experiments, laser Doppler flow
(LDF) was monitored using a flexible 0.5 mm fibreoptic probe
(Perimed, Stockholm, Sweden) attached to the intact skull overlying
the MCA territory. LDF changes were measured during ischaemia
Fig. 1 Generation and initial characterization of VEGF transgenic mice. (A) Brain-specific transcription of human VEGF165 is controlled by
the rat NSE promoter or regulatory sequences spanning from the promoter (P), to exon 1 and 2 (1, 2), the first two introns (I, II) up to exon 3
(3) of the mouse NMDAR e2 gene in the transgenic constructs. (B–E) Brain-specific expression was checked by in situ hybridization
analysis in brains from the NSE-VEGF transgenic line V1 (B, C and E) and the NMDAR-VEGF line V6 (D) with a 35S-labelled riboprobe
recognizing both mouse and human VEGF mRNA. Specific hybridization signals are present in dentate gyrus (DG), hippocampus (HIP)
and cortex (CTX) of transgenic animals (B and D), but not of non-transgenic littermates (V1, E), where endogenous mouse VEGF
expression in epithelial cells of the choroid plexus (CP) and in astrocytes is shown. No specific signal is detectable with a VEGF sense
probe (V1, C). Bar = 500 mm.
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and up to 30 min after reperfusion onset. At that time, anaesthesia
was discontinued. After 24 (90 min MCA occlusion) or 72 h (30 min
ischaemia) of reperfusion, neurological deficits were evaluated using
a 5-point neurological deficit score ranging from 0 = normal function
to 4 = absence of spontaneous motor activity (Hata et al., 1998).
Sodium fluorescein extravasation
Immediately thereafter, one subset of animals [n = 6/group (90 min
MCA occlusion) and n = 7–8/group (30 min ischaemia)] was
re-anaesthetized with halothane. Vascular permeability was assessed
with sodium fluorescein, as described (Schoch et al., 2002), except
that fluorescence of the supernatant was measured at 485 nm at an
excitation wavelength of 330 nm using a fluoroscope (GENios Pro,
TECAN’s advanced, multi-functional injector reader). Measured
values are shown as relative fluorescence units (r.f.u.) per mg of
brain tissue.
CBF autoradiography
At the same time, another subset of animals submitted to 90 min
ischaemia (n = 5/group) received intraperitoneal injections of 0.2 mCi
4-iodo-N-methyl-[14C]antipyrine (IAP) (Amersham Life Sciences,
Freiburg, Germany). Two minutes later, animals were decapitated,
and arterial blood samples (50–100 ml) were taken from the animals’
trunks, which subsequently were measured in a liquid scintillation
counter. Brains were quickly removed and frozen with dry ice. Sec-
tions of 20 mm were prepared, dried on a hot plate and exposed
to X-ray film (Amersham Hyperfilm) with calibrated 14C-labelled
standards. Using an image processing system (ImageMG, NIH,
Bethesda, MD), CBF was calculated, as previously described
(Maeda et al., 2000; Kilic et al., 2001).
Cresyl violet staining
Coronal brain sections from five equidistant rostrocaudal brain
levels, 2 mm apart, were submitted to cresyl violet staining (n =
11/group). Sections were digitized, and the border between infarcted
and non-infarcted tissue was outlined using an image analysis system
(Image J). On these sections, the areas of infarction, brain swelling
and infarct volume were determined, as previously described (Kilic
et al., 2001). Sections were also evaluated by measuring the distance
of the infarct border from the midline at the level of the striatum and
thalamus.
Terminal transferase-mediated dUTP nick
end labelling (TUNEL)
Brain sections were fixed for 20 min at 4C with 4% paraformal-
dehyde/0.1 M phosphate-buffered saline (PBS). TUNEL staining
was then performed, as previously described (Hermann et al.,
2001b). Shortly after labelling with terminal deoxynucleotidyl
transferase (TDT) mix, containing 12.5 mg/ml TDT (Boehringer-
Mannheim, Mannheim, Germany) and 25 mg/ml biotinylated dUTP
(Boehringer-Mannheim), sections were stained with fluorescein
isothiocyanate (FITC)-conjugated streptavidin, counterstained with
40,6-diamidino-2-phenylindole (DAPI) and coverslipped. Sections
were analysed by counting DNA fragmented cells in rectangular
fields measuring 25 000 mm2 in six regions of interest in the striatum
as previously described (Hermann et al., 2001b). Mean values were
calculated for these areas.
Immunohistochemistry
Sections were fixed in ice-cold acetone (CD31, VEGF receptor-2)
or 4% paraformaldehyde/0.1 M PBS (activated caspase-3), washed
and immersed for 1 h in 0.1 M PBS containing 0.3% Triton (PBS-T)/
10% normal goat serum. Sections were incubated overnight at 4C
with the following primary antibodies: (i) monoclonal rat anti-mouse
CD31 (catalogue number 557355; BD Biosciences, diluted 1 : 100);
(ii) monoclonal rat anti-mouse VEGF receptor-2 (Marti et al., 2000)
(diluted 1 : 100); or (iii) polyclonal rabbit anti-mouse activated
caspase-3 (Hermann et al., 2001b) (diluted 1 : 100). After washing,
sections were incubated in secondary Cy-3 antibodies, counter-
stained with DAPI and coverslipped. Sections were evaluated by
counting the number of CD31- and VEGF receptor-2-positive vessel
profiles or caspase-3-positive cells in rectangular fields, measuring
500 000 and 25 000 mm2, respectively.
Visualization of the anastomotic line between the
MCA and anterior cerebral artery (ACA)
Further animals (n = 3/group) were anaesthetized with halothane and
injected with a lethal dose of papaverine hydrochloride (50 mg/kg in
sterile water) over the right femoral vein. The thoracic aorta was
clipped and the ascending aorta cannulated with PE10 tubing. Warm
(38.0C) latex (Maeda et al., 1999) mixed with carbon black (10 ml/g)
was injected through the cannula with slight pressure (0.3 ml/animal
over 20 s). After 10 min, animals were decapitated and their brains
removed. Photographs were taken of the dorsal brain surfaces, which
allowed localization of the anastomotic lines between the MCA and
ACA territories by tracing peripheral branches to the points at which
vessels were connected, as previously described (Maeda et al., 1999).
The distance from the midline to the line of anastomosis was meas-
ured at coronal planes 4 and 6 mm from the frontal pole, respectively.
These levels corresponded closely to the striatal and thalamic levels,
at which infarct areas had been evaluated.
Statistics
All measurements were performed by two independent investigators
blinded to the experimental conditions. For statistical analyses, a
standard software package (SPSS for Windows 10.1) was used.
Values are given as means 6 SD. Differences between groups
were compared by using two-tailed t tests. P values <0.05 were
considered significant.
Results
Establishment of transgenic lines
To study the effects of elevated VEGF levels in the brain, we
designed a transgenic mouse model system in which VEGF
expression is specifically increased in neurons driven by the
rat NSE promoter or regulatory sequences derived from the
gene for the e2 subunit of the mouse NMDAR (Fig. 1A). Three
rounds of pronuclei microinjections yielded eight transgenic
NSE-VEGF and seven NMDAR-VEGF founders which were
confirmed by PCR of tail DNA. Three of the NSE-VEGF
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founders and five of the NMDAR-VEGF founders transmitted
the transgene to their offsprings and were used to establish
eight distinct heterozygous breeding lines: TgN(NSEVEGF)
1651–1653 (V1–V3) and TgN(NMDARVEGF) 1654–1658
(V4–V8) (Table 1). PCR analysis of living offspring revealed
that 60% of heterozygous mice from the NSE-VEGF lines V1
and V3 were non-transgenic, while only 40% of the offsprings
were transgenic, indicative of some embryonic lethality in
these two lines. Transgenic offsprings derived from all
other lines were born at equal frequency compared with
their non-transgenic littermates (data not shown).
Characterization of transgenic mice
Offspring from all eight lines were analysed for VEGF protein
expression in the brain. ELISA of human VEGF in brain tissue
showed a wide variation in level of expression (Table 1),
depending on the promoter type, and presumably transgene
copy number and integration site. Mean mouse VEGF protein
level in non-transgenic animals (3.36 1.3 ng of VEGF/g total
protein) was comparable in all lines examined, except for line
V1, in which mouse VEGF levels differed between transgenic
and non-transgenic animals (Table 1), indicative of attenua-
tion of endogenous VEGF production when human transgene
levels are high. Quantitatively, the maximal level of total
VEGF expression in the brain with each of the two promoters
increased by 650% in line V1 and 70% in line V6, respect-
ively, compared with the endogenous mouse VEGF protein
level. Animals originating from the five highest expressing
lines V1–V3, V5 and V6 were analysed further for transgene
mRNA expression in adult brain. In situ hybridization using
a human VEGF probe revealed a cross-reactivity with the
endogenous mouse VEGF mRNA. Expression analysis
showed that in all transgenic animals analysed, VEGF was
targeted appropriately to neuronal cells and strongly
expressed in dentate gyrus and hippocampus, but was also
found in cortex (Fig. 1B and D). In addition, a scattered
expression all over the brain was detected, which was also
present in non-transgenic control mice (Fig. 1E), thus repres-
enting the endogenous mainly astrocytic expression of
mouse VEGF mRNA as described before (Marti and Risau,
1998; Schoch et al., 2002). All subsequent work was per-
formed in heterozygous transgenic animals and non-transgenic
littermates derived from the highest VEGF-expressing NSE-
VEGF line V1. Non-transgenic and transgenic animals
exhibited normal growth and development without detectable
anatomical, physiological or behavioural abnormalities (Vogel
et al., 2004). Physiological monitoring with regard to body
weight, blood gases and pH, haematocrit, heart rate and
arterial blood pressure revealed no significant differences
between the experimental groups (Vogel et al., 2004).
LDF during and after ischaemia
LDF measurements during and after 90 and 30 min of MCA
occlusion exhibited no differences between transgenic and
non-transgenic mice. In all animal groups, thread insertion
resulted in a decline of blood flow to 25% of pre-ischaemic
levels. After thread retraction, blood flow rapidly reached pre-
ischaemic values in animals submitted to 90 min ischaemia.
In animals subjected to 30 min ischaemia, a hyperperfusion
reaction was found shortly after reperfusion (to 120–140%
of pre-ischaemic levels).
VEGF overexpression attenuates
post-ischaemic neurological deficits
and ischaemic injury
Reproducible neurological deficits and brain infarcts were
noticed after 90 min MCA occlusion. VEGF overexpression
significantly reduced infarct volume (Fig. 2A and B)
and improved neurological abnormalities (Fig. 2C) at 24 h
after stroke. To rule out that differences in infarct size in
transgenic mice were due to macroscopic changes in the
size of the MCA territory which exist in different mouse
strains (Maeda et al., 1999), animals received latex infusions
to assess the localization of anastomotic lines between the
MCA and ACA territories (Fig. 3A). Latex infusions revealed
that anastomotic lines did not differ between transgenic and
non-transgenic mice, either at the striatal or at the thalamic
level (Fig. 3B), demonstrating that the observed differences in
the localization of the infarct border (Fig. 3C) were indeed
caused by VEGF overexpression.
After 30 min of ischaemia, neurological deficits were
always mild irrespective of the genotype of the mice (deficit
score <1 in all animals). However, widespread neuronal
injury was detected in the striatum, but not the overlying
Table 1 Human VEGF165 transgene and endogenous
mouse VEGF expression
Promoter Line tg/ntg hVEGF n mVEGF n
NSE V1 tg 21.74 6 1.38 4 1.52 6 0.27** 3
ntg 0.40 6 0.62 5 3.48 6 0.74 5
V2 tg 4.90 6 1.68 7 NA
ntg ND 1 NA
V3 tg 16.57 6 4.04 5 2.52 6 1.35 5
ntg 0.29 6 0.57 4 3.40 6 0.89 3
NMDAR V4 tg 1.14 6 0.78 8 3.05 6 1.44 6
ntg 0.51 6 0.62 6 3.39 6 2.31 4
V5 tg 2.57 6 2.33 3 NA
ntg ND 2 NA
V6 tg 2.19 6 0.93 8 3.12 6 1.13 6
ntg 0.68 6 0.88 3 3.03 6 1.18 3
V7 tg 0.96 6 0.21 3 NA
ntg ND 3 NA
V8 tg 1.15 6 1.0 3 NA
ntg ND 2 NA
Human and mouse VEGF protein levels (ng/g total protein) were
quantified in the brain of non-transgenic (ntg) and transgenic (tg)
mice from all generated mouse lines (V1–V8) using commercially
available ELISA kits. Means 6 SD (**P < 0.01 versus
non-transgenic control). NA = not analysed; ND = not detectable.
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cortex at 3 days of reperfusion. VEGF overexpression sig-
nificantly reduced the density of injured cells in the striatum,
as judged from the reduced number of TUNEL-positive, i.e.
DNA fragmented, cells. Quantification revealed a 41% reduc-
tion in the density of DNA fragmented cells in transgenic mice
(Fig. 4A). This tissue protection coincided with a reduction of
caspase-3 activity in the same area (Fig. 4B). Thus, VEGF
overexpression resulted in neuroprotection after 24 h which
was sustained after 3 days and accompanied by improvements
in neurological behaviour.
VEGF causes a mild BBB dysfunction
As VEGF is a potent inducer of vascular leakage leading to
brain oedema formation, we next analysed histological brain
swelling indicating major damage of the BBB as well as BBB
permeability. To this end, sodium fluorescein was injected as
a permeability marker at 24 h and 3 days after ischaemia, and
animals were sacrificed 30 min thereafter. Brain swelling was
not influenced by VEGF overexpression (Fig. 5A). However,
sodium fluorescein extravasation revealed an increased BBB
permeability in transgenic mice as compared with control
animals both after 90 min ischaemia/24 h reperfusion
(Fig. 5B) and after 30 min ischaemia/3 days reperfusion
(Fig. 5C), although the absolute level of BBB damage was
far less pronounced in the latter group.
VEGF overexpression and angiogenesis
Vascular density was significantly increased in non-ischaemic
transgenic mice compared with non-transgenic controls in
both the cerebral cortex (143 6 12 versus 97 6 14 vessels/
square; P < 0.01) and striatum (91 6 10 versus 67 6 8; P <
0.01), coinciding with the increased capillary density pre-
viously shown in other brain areas (Vogel et al., 2004).
After 90 min ischaemia/24 h reperfusion, the number of
VEGF receptor-2-positive endothelial cells indicating new
vessel growth was equal in transgenic and non-transgenic
mice, in both the ischaemic and surrounding non-ischaemic
tissue (data not shown). At 3 days reperfusion (after 30 min
MCA occlusion), the density of newly formed blood
vessels was higher in ischaemic compared with adjacent
non-ischaemic areas; however, only in transgenic, but not
non-transgenic animals (Fig. 6A). Quantification of vessel
profiles revealed a significant increase in vessel density both
in the cerebral cortex (Fig. 6B), and, even more pronounced,
in the striatum of transgenic mice (Fig. 6C). Thus, the higher
VEGF levels in the transgenic mice resulted in a faster and
more pronounced angiogenic response, which was most dis-
tinct in areas exhibiting neuronal injury (i.e. the striatum).
Increased vessel density promotes
haemodynamic steal flow
An increased vessel density will facilitate neuronal survival
only when it is associated with an increased CBF, resulting in
a rise of oxygen and nutrient delivery. We therefore analysed
regional CBF using the IAP autoradiography technique in
transgenic and non-transgenic mice after 90 min ischaemia/
24 h reperfusion. Surprisingly, we found a dramatic decrease in
CBF in the ischaemic MCA territory of VEGF-overexpressing,
compared with non-transgenic mice (Fig. 7). Quantitative
Fig. 2 Brain-specific overexpression of VEGF reduces infarct size
and improves neurological deficits. Mice underwent 90 min of
MCA occlusion followed by 24 h reperfusion, and infarct size was
measured by cresyl violet staining (A). Infarct quantification
revealed significantly reduced infarct volumes in VEGF
transgenic mice (VEGF-tg) compared with non-transgenic controls
(ntg) (B). The smaller infarcts were associated with a significant
reduction in neurological deficit scores (C). Values are means 6
SD (n = 11 animals/group). **P < 0.01 compared with
non-transgenic mice.
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analysis revealed a reductionofblood flowvalues in the parietal
cortex by 58% (Table 2). Blood flow was also reduced in the
sensory cortex by 46%. In the motor cortex, i.e. in the area close
to the infarct border, CBF reduction was only 16% and not
significantly different from non-transgenic animals (Table 2).
Thus, the reduction in CBF appears to be most prominent in
the ischaemic core, but less pronounced towards the ischaemic
border. On the other hand, we noticed a significant increase
in regional CBF by 59% in the non-ischaemic cingulate cortex,
which is supplied by the ACA, in VEGF-overexpressing ani-
mals compared with controls (Fig. 7; Table 2). CBF in the
remote basal forebrain did not differ between transgenic and
non-transgenic animals (Table 2). These data suggest that the
higher vessel density in transgenic animals promotes a pro-
nounced steal of blood flow from ischaemic to non-ischaemic
areas which becomes more apparent towards the core of the
ischaemic area.
Discussion
The main finding of the present study is that brain-selective
VEGF overexpression provides neuroprotection against focal
cerebral ischaemia, reflected by smaller infarct volume,
reduced disseminated neuronal injury and better neurological
outcome, although regional blood flow is significantly
decreased due to a haemodynamic steal effect. Our data
indicate that the beneficial effect of VEGF is due mainly to
its direct neuroprotective action, i.e. by inhibition of cell
death pathways, rather than angiogenic function.
VEGF overexpression and angiogenesis
VEGF is the major angiogenic factor during development
(Risau, 1997), but, in adaptation to tissue hypoxia, can also
induce new vessel growth in the adult organism, allowing
increased transportation of oxygen and nutrients to the tissue
at risk (LaManna and Harik, 1997). In a model of permanent
focal cerebral ischaemia, we previously have shown that
VEGF gene expression increased in the penumbra as early
as 6 h after the onset of ischaemia, resulting in new vessel
growth in the ischaemic area within 48 h after MCA occlusion
(Marti et al., 2000). In line with these findings, we show here
that apart from the constitutively increased vessel density in
transgenic mice, VEGF overexpression stimulates new vessel
growth in ischaemic areas. Our data indicate a synergistic
Fig. 3 No changes in the gross anatomy of the middle cerebral artery (MCA) territory between VEGF-overexpressing and control mice.
The distance from the midline of the anastomotic line between the MCA and anterior cerebral artery (ACA) vascular territory was
determined at the level of the striatum and thalamus. To this end, latex mixed with carbon black was injected through the cannulated
aorta. Anastomotic lines between the MCA and ACA territories were determined by tracing peripheral branches on dorsal brain surfaces of
VEGF transgenic (VEGF-tg) and non-transgenic (ntg) control mice (A) to the points at which vessels were connected (indicated by dotted
lines). The lack of difference indicates that both mouse groups have the same MCA territory size (B). The significant differences in the
localization of the infarct border as determined by cresyl violet staining in transgenic mice compared with controls (C) thus reflects a
neuroprotective effect of VEGF. Values are means 6 SD [n = 3 animals/group (latex studies) and n = 11/group (cresyl violet staining)].
*P < 0.05 compared with non-transgenic mice. Bar = 1 mm.
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action of transgenic human VEGF165 and hypoxically induced
mouse VEGF, thus further increasing vessel density in
ischaemic areas.
VEGF-induced angiogenesis has been considered as treat-
ment in ischaemic disease (Rivard and Isner, 1998). Prelimin-
ary clinical studies for the treatment of peripheral arterial
occlusive diseases (Baumgartner et al., 1998) and myocardial
ischaemia (Hendel et al., 2000) were promising; however,
results from the larger VIVA trial were somewhat disappoint-
ing (Henry et al., 2003). A reason for the relatively poor
beneficial effect might be the absence of increased blood
flow in the ischaemic tissue, as suspected in this trial
(Henry et al., 2003). We now were able to show in our
mice overexpressing VEGF that a higher capillary density
does not automatically result in an improvement of blood
flow. It has been suggested that vascular remodelling
might be suboptimal after isolated VEGF application and
that additional angiogenic factors, such as angiopoietins
and platelet-derived growth factor (PDGF), are needed for
a normal remodelling process (Bruick and McKnight,
2001). Indeed, we previously showed that CBF in transgenic
animals was scarcely increased despite a nearly 3-fold
increase in capillary density (Vogel et al., 2004). Nevertheless
after maximal vasodilatation, CBF in transgenic animals
was increased to a significantly greater extent compared
with controls, demonstrating that an additional vessel capacity
that is provided by isolated VEGF overexpression can be
recruited and results in increased organ perfusion (Vogel
et al., 2004). However, based on our current data, we conclude
that the surplus in vessel density and thus the capacity to
increase CBF is ineffective in the MCA territory. On the
Fig. 4 VEGF overexpression reduces disseminated neuronal cell
death. Mice underwent 30 min of MCA occlusion followed by
3 days reperfusion, and disseminated cell death was analysed in
the striatum by visualization of DNA strand breaks labelled by
TUNEL staining and caspase-3 activation detected by staining
with an antibody against activated caspase-3. Quantification
revealed significantly reduced DNA fragmented (A) as well as
activated caspase-3-positive (B) cells in VEGF transgenic
mice compared with non-transgenic controls. Values are
means 6 SD (n = 7–8 animals/group). *P < 0.05 compared with
non-transgenic mice.
Fig. 5 VEGF overexpression has no effect on brain swelling, but
induces mild BBB dysfunction. Analysis of cresyl violet-stained
brain sections after 90 min ischaemia/3 days reperfusion revealed
no changes of brain swelling in VEGF transgenic mice (A).
However, determination of subtle changes in BBB function by
quantification of sodium fluorescein extravasation revealed a
significant increase in vascular permeability in transgenic mice,
both after 90 min MCA occlusion/24 h reperfusion (B) and after
30 min ischaemia/3 days reperfusion (C). Note that vascular
leakage was less pronounced after mild ischaemia (C). Values are
means 6 SD [n = 6–8 animals (sodium fluorescein) and n = 11
animals (brain swelling)/group]. **P < 0.01 compared with
non-transgenic mice.
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contrary, CBF in the MCA area was even significantly
reduced in transgenic animals compared with non-transgenic
mice, while the higher vascular density resulted in an
increased CBF outside the MCA territory in the ischaemia-
remote cortex, such as the cingulate cortex, which is supplied
by the ACA. These results indicate that blood flow in ischae-
mic areas is compromised by a steal of circulating blood to
non-ischaemic areas. In ischaemic stroke, such steal phenom-
ena are well known from vasodilator therapies, e.g. with
calcium antagonists, which may improve blood flow outside
an ischaemic region, but can cause a deterioration in perfusion
of tissue at risk (Strandgaard and Paulson, 1990). In addition,
it has been shown that adenovirus-mediated application of
VEGF resulted in similar steal effects (Vogel et al., 2003).
These data indicate that therapeutic angiogenesis for stroke
patients by application of VEGF is far more complex than
initially thought (Greenberg, 1998; Croll and Wiegand, 2001).
Taken together, our findings argue against major haemo-
dynamic benefits of angiogenesis, at least during one single
stroke event. On the other hand, stimulation of angiogenesis
may be beneficial when subsequent episodes of ischaemia in
the same vascular territory are expected, e.g. in the clinical
situation because of localized ulcerated plaques or arterial
stenosis. However, proper vascular remodelling as well as
the contribution of newly formed vessels for local CBF
must be carefully investigated.
VEGF overexpression induces post-ischaemic
neuroprotection
Our data strongly indicate a powerful direct neuroprotective
function of VEGF, as brain damage after focal ischaemia is
significantly attenuated in VEGF-overexpressing mice, both
Fig. 6 Increased angiogenesis in ischaemic brain tissue of VEGF-overexpressing mice. Formation of new blood vessels was detected
after 30 min ischaemia/3 days reperfusion by immunohistochemistry for VEGF receptor-2, which mainly stains newly formed blood
vessels. VEGF receptor-2-positive endothelial cells were detected in both transgenic and non-transgenic mice, in the ischaemic
as well as non-ischaemic cortex (A). Quantification of VEGF receptor-2-positive vessels in cerebral cortex (B) and striatum (C)
revealed a significantly higher number of stained vessels only in the ischaemic tissue of transgenic animals, but not in non-ischaemic
areas nor in non-transgenic mice, suggestive of increased angiogenesis in ischaemic areas of VEGF-overexpressing mice. Values
are means 6 SD (n = 6–8 animals/group). *P < 0.05 and **P < 0.01 compared with non-transgenic mice. Scale bar = 200 mm.
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after longer lasting ischaemia (90 min) leading to brain infarc-
tion and after mild ischaemia (30 min) associated with dis-
seminated neuronal injury. The protective effect of VEGF is
associated with an inhibition of caspase-3 activity, suggesting
that VEGF inhibited executive cell death pathways, in line
with previous studies showing neuroprotection after VEGF
treatment, both in vitro (Matsuzaki et al., 2001) and in vivo
(Sun et al., 2003). It appears that VEGF receptor-2 as well as
neuropilin-1 are transducing the protective signal (Matsuzaki
et al., 2001), possibly leading to subsequent activation of
phosphatidylinositol 3-kinase/Akt and extracellular-regulated
kinase (ERK-1/-2) pathways (recently reviewed by Marti,
2002; Rosenstein and Krum, 2004). Recent data suggest
that VEGF can also act on the neuronal microtubular content,
which is involved with growth, stability and maturation of
neural cells (Rosenstein et al., 2003). Taken together, VEGF
could play a significant role in brain repair and emerges more
and more as a central player in neurodegenerative disorders
(Storkebaum and Carmeliet, 2004) with potent direct neuro-
protective (Marti, 2002; Sun et al., 2003) and neurotrophic
(Sondell et al., 1999; Rosenstein et al., 2003) functions.
VEGF overexpression causes mild
BBB dysfunction
Finally, when VEGF therapy for stroke patients is considered,
the potent permeability-inducing effect of this factor (Senger
et al., 1983) must be borne in mind. Oedema formation
depends on VEGF dosage, application time and localization
(topical or systemic), as well as on concomitant activation of
VEGF receptors. In our VEGF transgenic animals, cerebral
vessels appear tight and non-leaky (Vogel et al., 2004), prob-
ably due to the absence of VEGF receptor activation which
is commonly associated with vasogenic oedema formation
(Croll and Wiegand, 2001). Similarly, chronic intraventri-
cular infusion of VEGF into normal non-ischaemic rat
brain resulted in a dose-dependent increase in vessel density
and vascular permeability, though without a corresponding
increase of brain water content (Harrigan et al., 2002).
Accordingly, we were unable to detect detrimental effects
of VEGF overexpression on brain oedema formation after
MCA occlusion although enhanced angiogenesis mildly
increased BBB leakage as assessed by sodium fluorescein.
The degree of vascular leakage was comparable with the
effect observed when mice were subjected to severe systemic
hypoxia (Schoch et al., 2002). It is difficult to predict whether
clinical CNS symptoms associated with hypoxia, e.g. during
exposure to high altitude (Hackett and Roach, 2001), could
be the consequence of such a mild BBB dysfunction. BBB
opening can disturb local ion concentrations and thus might
interfere with proper neural function (Bradbury, 1993).
Behavioural tests with VEGF transgenic mice, however,
revealed no differences when compared with non-transgenic
littermates (unpublished own observation), arguing against a
significant effect of the mild BBB opening. Gross breakdown
of the BBB will certainly cause vasogenic cerebral oedema
and even result in the transmigration of activated leukocytes
(Petty and Lo, 2002). In fact, when high doses of VEGF were
delivered to the brain of normal rats, detrimental oedema
formation causing animal death has been observed (Vogel
et al., 2003).
Several reports deal with the effect of VEGF application
to the CNS. It appears that application time and localization
play crucial roles in the outcome after cerebral ischaemia.
Fig. 7 VEGF overexpression induces haemodynamic steal
phenomena in the ischaemic brain. Regional CBF in various brain
areas of non-transgenic and VEGF-overexpressing mice submitted
to 90 min MCA occlusion/24 h reperfusion was determined by
4-iodo-N-methyl-[14C]antipyrine autoradiography. Blood flow
was markedly reduced in the ischaemic parietal cortex (PC), and
increased in the non-ischaemic cingulate cortex (CC) in VEGF
transgenic mice.
Table 2 Quantification of regional CBF in VEGF-overexpressing mice (tg) and controls (ntg)
Cingulate
cortex
Motor
cortex
Sensory
cortex
Parietal
cortex
Dorsolateral
striatum
Ventromedial
striatum
Basal
forebrain
ntg 69.0 6 29.9 75.3 6 22.6 113.2 6 34.9 75.5 6 47.1 43.8 6 44.4 57.1 6 59.9 80.7 6 19.5
tg 109.6 6 36.1* 63.2 6 32.1 60.6 6 31.6* 32.0 6 10.5* 28.4 6 38.6 27.3 6 37.9 79.5 6 36.3
Quantification of regional CBF was calculated from IAP autoradiographies. Values are mean 6 SD (n = 5 animals/group); *P < 0.05
compared with non-transgenic mice.
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Topical application of VEGF on the surface of the reperfused
rat brain after 90 min MCA occlusion resulted in a significant
reduction of infarct volume and oedema formation, associated
with reduced neuronal damage (Hayashi et al., 1998). Local
VEGF levels may not suffice to increase vascular permeabil-
ity in sufficient microvessels to cause oedema formation. In
analogy, a recent study has shown that local tissue concentra-
tions of VEGF critically determine whether proper angiogen-
esis takes place or abnormal vasculature is formed (Ozawa
et al., 2004), pointing to the importance of having the right
amount of VEGF at the right place. Beneficial effects of
systemic VEGF application, on the other hand depend on
the time point of treatment.
When VEGF was delivered in the acute stage after stroke,
the BBB was damaged and this damage may have compro-
mised the beneficial neuroprotective actions of VEGF (van
Bruggen et al., 1999). Late administration of VEGF, i.e. on
days 1–3 of reperfusion, however, improved neurological out-
come (Zhang et al., 2000; Sun et al., 2003). Finally, 6–12 days
of VEGF pre-treatment using an intraventricularly applied
adeno-associated virus gene transfer system was associated
with an improvement of global brain ischaemia injury in
gerbils (Bellomo et al., 2003).
All these data indicate the crucial importance of proper
application time and dosage of VEGF (Zhang et al., 2000).
It appears that the acute early increase in VEGF levels pro-
vokes oedema formation resulting in a detrimental outcome,
while delayed activation or moderately augmented but steady
VEGF levels favour its neuroprotective effect. The detailed
study of acute changes elicited by exogenous VEGF applica-
tion, however, will require transgenic mice with inducible
VEGF expression in the brain (Dor et al., 2002).
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